Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Metastatic spinal cord compression

Palliative and end-of-life care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Suspected malignant cord compression

Cancer with new neurological deficit, gait loss, sensory change or bladder or bowel dysfunction is MSCC until urgent imaging proves otherwise. Severe mechanical spinal pain may also indicate instability with risk during movement.

Action: Contact the MSCC coordinator or acute oncology team immediately, assess and document neurology, support neutral alignment if instability is suspected, give dexamethasone 16 mg for neurological features, provide analgesia and obtain whole-spine MRI within 24 hours. Discuss surgery and radiotherapy as soon as imaging is available.

Synopsis

Recognise malignant spinal cord or cauda-equina compression before irreversible disability, protect the spine, obtain whole-spine MRI within the correct timeframe and coordinate dexamethasone, surgery, radiotherapy, rehabilitation and goal-concordant supportive care.

  • Metastatic spinal cord compression is an oncological emergency: new weakness, gait change, sensory loss, radicular pain or bladder and bowel dysfunction in a person with cancer needs immediate MSCC-pathway contact.
  • Pain often precedes neurological loss. Progressive night pain, movement pain, coughing or straining pain and a band-like radicular quality are high-risk patterns.
  • First-line examination records power, reflexes, sensory level, gait if safe, saddle sensation, anal function when indicated, bladder retention and spinal tenderness without forcing movement.
  • Gold-standard imaging is urgent MRI of the whole spine with axial sequences through abnormalities; complete it within 24 hours when MSCC is suspected.
  • Do not use a normal plain spinal radiograph to exclude metastasis or cord compression. Use CT with multiplanar reconstruction when MRI is contraindicated and myelography only after specialist discussion.
  • Give dexamethasone 16 mg orally, or an equivalent parenteral dose, as soon as possible for neurological symptoms or signs while definitive treatment is arranged.
  • Protect alignment when instability is suspected, provide analgesia and pressure care, but avoid prolonged flat bed rest once stability and safe mobilisation have been assessed.
  • Spinal surgical and oncology teams decide decompression or stabilisation versus urgent radiotherapy from neurological trajectory, imaging, mechanical stability, tumour biology, prognosis and patient goals.
  • Preserve function beyond tumour treatment: plan bladder and bowel care, thrombosis prevention, skin protection, rehabilitation, equipment and discharge support from the start.
  • Document the pre-treatment neurological baseline and time of every step because delay can convert reversible impairment into permanent paralysis.

Key red flags

New limb weakness, gait disturbance or inability to stand in a person with current or previous cancer is an emergency.

Urinary retention, loss of bladder sensation, saddle numbness or faecal incontinence suggests conus or cauda-equina compromise.

A truncal sensory level, bilateral radicular pain or rapidly ascending numbness localises possible cord disease.

Severe movement-related pain or deformity suggests mechanical instability and makes unsupported mobilisation hazardous.

Fever, immunosuppression or recent bacteraemia with spinal pain raises epidural abscess as an equally urgent alternative.

A normal plain radiograph does not exclude vertebral metastasis, epidural tumour or cord compression.

Steroids before tissue diagnosis can complicate suspected lymphoma or myeloma; obtain immediate specialist advice without delaying neural rescue.

Rapid neurological progression

Declining power, inability to stand or new sphincter dysfunction demands immediate MSCC coordination and imaging rather than routine outpatient referral.

Investigation priorities

01
Immediate neurological and stability assessmentFirst step

Document power, reflexes, sensory level, saddle and sphincter features, gait only if safe, spinal pain, deformity and last functional baseline.

Management branches

Immediate pathwayProtect neurology while obtaining MRI

A person with cancer develops weakness, gait, sensory or sphincter change suggesting MSCC.

  1. Contact the named MSCC service immediately, record neurological baseline and timing, assess instability and support alignment while providing adequate analgesia.
  2. Give dexamethasone 16 mg by a feasible route for neurological symptoms or signs, monitor glucose and obtain whole-spine MRI within 24 hours.
  3. Send images promptly for spinal surgical and oncology review and communicate the likely options, uncertainty and interim movement plan to patient and team.

Key medicines

Immediate dexamethasone for neurological MSCCGive 16 mg orally as soon as possible, or an equivalent parenteral dose when oral treatment is unreliable, then continue 16 mg daily while awaiting surgery or radiotherapy and taper after definitive treatment begins.Monitor glucose, infection, delirium, sleep, proximal weakness and gastrointestinal risk; discuss severe pain without deficit and suspected haematological malignancy with specialists before routine use.
Goal-matched analgesia during spinal rescueUse regular paracetamol when appropriate plus immediate-release opioid titrated to pain and renal function, converting to a stable regular regimen once requirement is known; add neuropathic treatment only after safety review.Avoid masking neurological reassessment through avoidable sedation; prescribe bowel care with opioids and monitor respiratory rate, cognition, renal clearance and movement-related breakthrough pain.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG234 spinal metastases and MSCCRecognition, imaging deadlines, dexamethasone, surgery, radiotherapy, immobilisation and rehabilitation.
  • BNF dexamethasone monographRoutes, adverse effects, interactions and monitoring for systemic corticosteroid treatment.
  • NICE NG89 thrombosis preventionIndividual venous-thromboembolism and bleeding assessment during hospital admission and immobility.
  • NICE CG140 strong opioids in palliative careOpioid initiation, rescue dosing, adverse-effect prevention and review.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom